Cellective Dx announced that it brought in a $5 million bridge to a $25 million second round of funding. The Mountain View, Calif.-based company will use the money to continue development of cancer diagnostic tools that analyze tumor cells in blood. The method is supposed to help doctors determine the best course of treatment.
The funding is expected to last through the end of 2010. That’s enough to span two more commercialized tests of the products, VentureWire reports. The bridge was provided by previous investors Mohr Davidow Ventures and Northgate Capital. The company, formerly named CellPoint Diagnostics, has brought in $19 million in capital total, having closed an $11.2 million first round last September.
